301301 川宁生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)10.77914.2897.4992.3615.038
总资产报酬率 ROA (%)7.3909.1634.1461.1492.311
投入资产回报率 ROIC (%)8.1849.9854.4871.2433.265

边际利润分析
销售毛利率 (%)35.31231.57424.79822.21321.590
营业利润率 (%)28.78123.24914.2686.9197.635
息税前利润/营业总收入 (%)29.31924.43415.9839.64912.521
净利润/营业总收入 (%)23.98219.50010.7713.4456.275

收益指标分析
经营活动净收益/利润总额(%)102.443105.081118.651169.12499.022
价值变动净收益/利润总额(%)-0.719-1.318-1.8372.8980.755
营业外收支净额/利润总额(%)-1.157-0.330-11.790-66.783-0.932

偿债能力分析
流动比率 (X)1.9231.5601.6721.2551.381
速动比率 (X)1.4890.8991.1610.6880.778
资产负债率 (%)31.40331.22040.22949.50852.966
带息债务/全部投入资本 (%)17.78821.56835.03344.96749.241
股东权益/带息债务 (%)429.289349.970184.124121.635102.908
股东权益/负债合计 (%)218.056219.900148.436101.85888.685
利息保障倍数 (X)33.81019.3744.9641.7542.526

营运能力分析
应收账款周转天数 (天)47.48960.66878.13289.692100.670
存货周转天数 (天)113.077166.893177.739207.786180.590